Apomorphine response and subtyping of schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Schizophrenia is a chronic mental disorder with limited treatment options.
• Apomorphine, a dopamine agonist, has been investigated for its potential therapeutic effects in psychiatric conditions.

Purpose of the Study:

• To evaluate the acute effects of low-dose apomorphine in patients with chronic schizophrenia.
• To explore the relationship between neuroimaging findings and treatment response.

Main Methods:

• A double-blind, placebo-controlled study was conducted.
• Twelve patients with chronic schizophrenia received either apomorphine (0.01 mg/kg) or placebo.
• Patients were assessed using the Brief Psychiatric Rating Scale.
• Computed tomography (CT) scans were used to categorize patients based on brain structure.

Main Results:

• No significant overall therapeutic difference was observed between apomorphine and placebo.
• Apomorphine significantly improved anxiety and depression subscales of the Brief Psychiatric Rating Scale.
• Patients with abnormal CT scans (e.g., enlarged ventricles) showed improvement or no change, while those with normal scans tended to worsen.

Conclusions:

• Low-dose apomorphine may have specific benefits for anxiety and depression in schizophrenia.
• Neuroimaging findings, such as CT scan abnormalities, may predict differential responses to apomorphine treatment.
• Further research is warranted to elucidate the role of apomorphine in schizophrenia management.